MONTREAL, May 31, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Elif McDonald has joined the team as Senior Director, Investor Relations.
“We are pleased to welcome Elif to lead our dedicated in-house investor relations efforts,” said Paul Lévesque, President and Chief Executive Officer, Theratechnologies. “Her comprehensive investor relations experience and robust network across the healthcare and financial communities will be a great asset as we advance awareness of our strong commercial portfolio, extensive research pipeline and vision for the future within capital markets. We look forward to enhancing our engagement with the investment community as we continue to strive for breakthrough therapies in human health while seeking further growth opportunities.”
“I am excited to join a world-class team of professionals with a collaborative culture committed to improving patient outcomes,” said Ms. McDonald. “Theratechnologies has developed a dynamic pipeline, brought life enhancing drugs to market, built a revenue generating commercial business, all while delivering a unique investment proposition. I look forward to elevating the Company’s visibility across capital markets and effectively communicating the corporate business strategy.”
Ms. McDonald brings a wealth of experience earned over 20 years in capital markets, investor relations, financial communications, and corporate governance. She has extensive experience managing investor relations platforms for companies of diverse market capitalizations and sectors, with a focus on Biotech and Pharmaceutical firms listed on the NYSE, NASDAQ and TSX. She has worked with leading financial institutions, as well as with renowned communications and governance experts in Canada and the United States. She is a graduate of the University of Ottawa with a bachelor’s degree in Economics.
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company’s website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “promising”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding our commercial portfolio, research pipeline and the development of new medicines. Although the forward-looking information contained in this press release is based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information. Certain assumptions made in preparing the forward-looking statements include that: sales of EGRIFTA SV® and Trogarzo® in the United States will increase over time; the Company’s commercial practices in the United States will not be found to be in violation of applicable laws; the long-term use of EGRIFTA SV® and Trogarzo® will not change their respective current safety profile; no recall or market withdrawal of EGRIFTA SV® and Trogarzo® will occur; no laws, regulation, order, decree or judgment will be passed or issued by a governmental body negatively affecting the marketing, promotion or sale of EGRIFTA SV® and Trogarzo®; continuous supply of EGRIFTA SV® and Trogarzo® will be available; the Company’s relations with third-party suppliers of EGRIFTA SV® and Trogarzo® will be conflict-free and such third-party suppliers will have the capacity to manufacture and supply EGRIFTA SV® and Trogarzo® to meet market demand on a timely basis; no biosimilar version of EGRIFTA SV® will be approved by the FDA; the Company’s intellectual property will prevent companies from commercializing biosimilar versions of EGRIFTA SV® in the United States; results obtained in preclinical studies with respect to our oncology development program will be replicated into humans; and, the Company’s business plan will not be substantially modified; and our research programs will lead to the discovery of new drugs. Forward-looking information assumptions are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies’ control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, those related to or arising from: the Company’s ability and capacity to grow the sales of EGRIFTA SV® and Trogarzo® successfully in the United States; the Company’s capacity to meet supply and demand for its products; the market acceptance of EGRIFTA SV® and Trogarzo® in the United States; the continuation of the Company’s collaborations and other significant agreements with its existing commercial partners and third-party suppliers and its ability to establish and maintain additional collaboration agreements; the success and pricing of other competing drugs or therapies that are or may become available in the marketplace; the Company’s ability to protect and maintain its intellectual property rights in EGRIFTA SV® and tesamorelin; the Company’s ability to successfully conduct its Phase 1 clinical trial using TH1902 in various types of cancer; the discovery of a cure for HIV; the Company’s expectations regarding its financial performance, including revenues, expenses, gross margins, profitability, liquidity, capital expenditures and income taxes; and, the Company’s estimates regarding its capital requirements. We refer current and potential investors to the “Risk Factors” section of our Annual Information Form dated February 23, 2022 available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov as an exhibit to our report on Form 40-F dated February 24, 2022 under Theratechnologies’ public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law
Investor and Media Contact:
Senior Director, Investor Relations